

Special Issue

Advancements in Clinical Applications of Immune Checkpoint Inhibitors

Message from the Guest Editors

It has been more than ten years since the clinical use of immune checkpoint inhibitors (ICIs), and we are still trying to utilize them more effectively. This Special Issue aims to compile a collection of articles that highlight the latest advancements in the clinical research of immune checkpoint inhibitors, including but not limited to the following:

- Clinical trials evaluating the efficacy and safety of immune checkpoint inhibitors in different cancer types.
- Combination therapies involving immune checkpoint inhibitors.
- Management of adverse events related to immune checkpoint inhibitors.
- Biomarkers related to immune checkpoint inhibitor therapy.
- Timing to stop ICIs.

We invite the submission of original research articles, reviews, and case reports in this field.

Guest Editors

Dr. Yugo Ashino

Department of Respiratory Medicine, Sendai City Hospital, Sendai 982-8502, Miyagi, Japan

Dr. Ichiro Onoyama

Department of Obstetrics and Gynecology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Deadline for manuscript submissions

30 November 2024



Reports

an Open Access Journal
by MDPI

Impact Factor 0.8



mdpi.com/si/200301

Reports

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
reports@mdpi.com

[mdpi.com/journal/
reports](https://mdpi.com/journal/reports)





Reports

an Open Access Journal
by MDPI

Impact Factor 0.8



[mdpi.com/journal/
reports](https://mdpi.com/journal/reports)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Toshio Hattori

Visiting Professor, Graduate School of Public Health, Shizuoka
Graduate University of Public Health, Shizuoka 420-0881, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), FSTA, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.4 days after submission; acceptance to publication is undertaken in 2.1 days (median values for papers published in this journal in the first half of 2024).